US3565924A
(en)
|
1968-07-01 |
1971-02-23 |
Wisconsin Alumni Res Found |
25-hydroxycholfcalciferol
|
US3833622A
(en)
|
1969-03-17 |
1974-09-03 |
Upjohn Co |
Crystalline 25-hydroxycholecalciferol hydrate and structurally related compounds
|
US3974272A
(en)
|
1972-09-01 |
1976-08-10 |
Merck & Co., Inc. |
Palatable cholestyramine coacervate compositions
|
US3880894A
(en)
|
1974-05-24 |
1975-04-29 |
Wisconsin Alumni Res Found |
1,25-Dihydroxyergocalciferol
|
US4004003A
(en)
|
1974-08-28 |
1977-01-18 |
The Upjohn Company |
25-Hydroxycalciferol compounds for treatment of steroid-induced osteoporosis
|
US4335120A
(en)
|
1979-03-21 |
1982-06-15 |
Hoffmann-La Roche Inc. |
Administration of biologically active vitamin D3 and vitamin D2 materials
|
US4230701A
(en)
|
1979-03-21 |
1980-10-28 |
Hoffmann-La Roche Inc. |
Administration of biologically active vitamin D3 and vitamin D2 materials
|
JPS55139320A
(en)
|
1979-04-16 |
1980-10-31 |
Teijin Ltd |
Bone metabolism regulator
|
US4442093A
(en)
|
1981-05-15 |
1984-04-10 |
Kureha Kagaku Kogyo Kabushiki Kaisha |
Method for administering 24,25-dihydroxycholecalciferol to persons suffering from hypercalcemia
|
JPS57188520A
(en)
|
1981-05-15 |
1982-11-19 |
Kureha Chem Ind Co Ltd |
Antihyperkalemia
|
JPS5832823A
(en)
|
1981-08-20 |
1983-02-25 |
Chugai Pharmaceut Co Ltd |
Cancer eliminating agent
|
JPS58206524A
(en)
|
1982-05-26 |
1983-12-01 |
Kureha Chem Ind Co Ltd |
Antitumor agent
|
US4448721A
(en)
|
1982-09-20 |
1984-05-15 |
Wisconsin Alumni Research Foundation |
Hydroxyvitamin D2 compounds and process for preparing same
|
US4721613A
(en)
*
|
1982-12-13 |
1988-01-26 |
Alza Corporation |
Delivery system comprising means for shielding a multiplicity of reservoirs in selected environment of use
|
JPS59155309A
(en)
|
1983-02-22 |
1984-09-04 |
Teijin Ltd |
Active type vitamin d3 composition and its preparation
|
US4684524A
(en)
|
1984-03-19 |
1987-08-04 |
Alza Corporation |
Rate controlled dispenser for administering beneficial agent
|
US4555364A
(en)
|
1984-11-01 |
1985-11-26 |
Wisconsin Alumni Research Foundation |
Method for preparing 1-hydroxyvitamin D compounds
|
US4695591A
(en)
|
1985-03-29 |
1987-09-22 |
Schering Corporation |
Controlled release dosage forms comprising hydroxypropylmethylcellulose
|
US4668517A
(en)
|
1985-04-04 |
1987-05-26 |
Norwich Eaton Pharmaceuticals, Inc. |
Furazolidone dosage form
|
EP0207638B1
(en)
|
1985-06-04 |
1990-12-19 |
Teijin Limited |
Sustained-release pharmaceutical preparation
|
JPS61293911A
(en)
|
1985-06-24 |
1986-12-24 |
Teisan Seiyaku Kk |
Sustained release preparation
|
US5167965A
(en)
|
1987-02-09 |
1992-12-01 |
The Dow Chemical Company |
Palatable cholestyramine granules, tablets and methods for preparation thereof
|
US4892821A
(en)
|
1987-07-08 |
1990-01-09 |
Taisho Pharmaceutical Co., Ltd. |
Method for preparing vitamin D compounds
|
US4997824A
(en)
|
1987-07-22 |
1991-03-05 |
Teva Pharmaceutical Industries Ltd. |
Combination of cholecalciferol derivatives for the treatment of renal bone disease
|
US5104864A
(en)
|
1988-08-02 |
1992-04-14 |
Bone Care International, Inc. |
Method for treating and preventing loss of bone mass
|
US5602116A
(en)
|
1988-08-02 |
1997-02-11 |
Bone Care International, Inc. |
Method for treating and preventing secondary hyperparathyroidism
|
US5869473A
(en)
|
1988-08-02 |
1999-02-09 |
Bone Care International, Inc. |
Method for treating and preventing hyperparathyroidism
|
JP2893191B2
(en)
|
1988-11-08 |
1999-05-17 |
武田薬品工業株式会社 |
Controlled release matrix agent
|
JP2525478B2
(en)
|
1989-03-01 |
1996-08-21 |
帝人株式会社 |
Active Vitamin D with improved stability (3) Lower solid preparation
|
JPH02240024A
(en)
|
1989-03-13 |
1990-09-25 |
Ss Pharmaceut Co Ltd |
Composition for active type vitamin d3s preparation
|
US5026559A
(en)
|
1989-04-03 |
1991-06-25 |
Kinaform Technology, Inc. |
Sustained-release pharmaceutical preparation
|
GB9004544D0
(en)
|
1990-03-01 |
1990-04-25 |
Leo Pharm Prod Ltd |
Novel treatment ii
|
JP2845342B2
(en)
|
1990-04-28 |
1999-01-13 |
大正製薬株式会社 |
Vitamin D Lower 3 Derivative-Containing Solid Preparation Composition
|
JPH04198129A
(en)
|
1990-11-28 |
1992-07-17 |
Sumitomo Pharmaceut Co Ltd |
Active type vitamin d>=3*s-containing composition
|
JP2893140B2
(en)
|
1990-11-30 |
1999-05-17 |
エスエス製薬株式会社 |
Stable vitamin D preparation
|
JPH04288016A
(en)
|
1991-03-14 |
1992-10-13 |
Tokai Capsule Kk |
Production of soft capsule agent of active type vitamin d3s
|
NZ242271A
(en)
|
1991-04-09 |
1993-10-26 |
Takeda Chemical Industries Ltd |
Medicaments containing a vitamin d compound stabilised by a basic substance
|
US5693615A
(en)
|
1991-06-05 |
1997-12-02 |
The Procter & Gamble Company |
Therapeutic compositions for osteoinduction
|
US6011068A
(en)
|
1991-08-23 |
2000-01-04 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US6031003A
(en)
|
1991-08-23 |
2000-02-29 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US6001884A
(en)
|
1991-08-23 |
1999-12-14 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US6313146B1
(en)
|
1991-08-23 |
2001-11-06 |
Nps Pharmaceuticals, Inc. |
Calcium receptor-active molecules
|
US5266331A
(en)
|
1991-11-27 |
1993-11-30 |
Euroceltique, S.A. |
Controlled release oxycodone compositions
|
US5472712A
(en)
|
1991-12-24 |
1995-12-05 |
Euroceltique, S.A. |
Controlled-release formulations coated with aqueous dispersions of ethylcellulose
|
US5160742A
(en)
|
1991-12-31 |
1992-11-03 |
Abbott Laboratories |
System for delivering an active substance for sustained release
|
NZ254424A
(en)
|
1992-06-22 |
1997-09-22 |
Lunar Corp |
Pharmaceutical composition and use of 1 alpha hydroxy-pre-vitamin d
|
US5795882A
(en)
|
1992-06-22 |
1998-08-18 |
Bone Care International, Inc. |
Method of treating prostatic diseases using delayed and/or sustained release vitamin D formulations
|
US5354743A
(en)
|
1992-09-15 |
1994-10-11 |
Thys Jacobs Susan |
Method for the treatment of premenstrual syndrome with vitamin D
|
US5431917A
(en)
|
1992-10-08 |
1995-07-11 |
Japan Elanco Company, Ltd. |
Hard capsule for pharmaceutical drugs and method for producing the same
|
US5342626A
(en)
|
1993-04-27 |
1994-08-30 |
Merck & Co., Inc. |
Composition and process for gelatin-free soft capsules
|
JP2684587B2
(en)
|
1993-06-21 |
1997-12-03 |
呉羽化学工業株式会社 |
Inhibitor of bone loss in renal osteodystrophy
|
US6121469A
(en)
|
1993-12-23 |
2000-09-19 |
The Regents Of The University Of California |
Therapeutically effective 1α,25-dihydroxyvitamin D3 analogs
|
JPH07242550A
(en)
|
1994-03-02 |
1995-09-19 |
Teijin Ltd |
Therapeutic agent for secondary hyperparathyroidism
|
IL110117A0
(en)
*
|
1994-06-24 |
1994-10-07 |
Univ Ben Gurion |
Pharmaceutical compositions comprising vitamin-d analogs
|
SE9402422D0
(en)
|
1994-07-08 |
1994-07-08 |
Astra Ab |
New beads for controlled release and a pharmaceutical preparation containing the same
|
EP0769936A1
(en)
|
1994-07-22 |
1997-05-02 |
G.D. Searle & Co. |
Self-emulsifying drug delivery system
|
JPH0892098A
(en)
|
1994-09-27 |
1996-04-09 |
Teijin Ltd |
Therapeutic medicine for consumption
|
PL183499B1
(en)
|
1994-10-21 |
2002-06-28 |
Nps Pharma Inc |
Chemical compounds for modulating calcium receptors and pharmacological composition containing them
|
US5756123A
(en)
|
1994-12-01 |
1998-05-26 |
Japan Elanco Co., Ltd. |
Capsule shell
|
US20020183288A1
(en)
|
1995-04-03 |
2002-12-05 |
Bone Care International, Inc. |
Method for treating and preventing hyperparathyroidism
|
US20040043971A1
(en)
|
1995-04-03 |
2004-03-04 |
Bone Care International, Inc. |
Method of treating and preventing hyperparathyroidism with active vitamin D analogs
|
US6376479B1
(en)
|
1995-04-03 |
2002-04-23 |
Bone Care International, Inc. |
Method for treating and preventing hyperparathyroidism
|
US6242434B1
(en)
|
1997-08-08 |
2001-06-05 |
Bone Care International, Inc. |
24-hydroxyvitamin D, analogs and uses thereof
|
WO1997011053A1
(en)
|
1995-09-21 |
1997-03-27 |
Wisconsin Alumni Research Foundation |
Calcitriol derivatives and their uses
|
DE19549243A1
(en)
|
1995-12-21 |
1997-06-26 |
Schering Ag |
Pharmaceutical preparations containing clathrates of cyclodextrins and unnatural vitamin D analogues
|
US5939408A
(en)
|
1996-05-23 |
1999-08-17 |
Hoffman-La Roche Inc. |
Vitamin D3 analogs
|
NO971934L
(en)
|
1996-05-23 |
1997-11-24 |
Hoffmann La Roche |
Fluorinated vitamin D3 analogues
|
ES2181017T3
(en)
|
1996-08-26 |
2003-02-16 |
Takeda Chemical Industries Ltd |
PHARMACEUTICAL COMPOSITION CONTAINING A PROMOTING SUBSTANCE OF OSTEOGENESIS AND A POLYETHYLENE GLYCOL.
|
US5958451A
(en)
|
1996-09-03 |
1999-09-28 |
Yung Shin Pharm Ind. Co., Ltd. |
Process for producing porous, controlled-release capsules and encapsulated composition
|
US5976784A
(en)
|
1996-09-20 |
1999-11-02 |
Wisconsin Alumni Research Foundation |
Calcitriol derivatives and their uses
|
US6190591B1
(en)
|
1996-10-28 |
2001-02-20 |
General Mills, Inc. |
Embedding and encapsulation of controlled release particles
|
US8828432B2
(en)
|
1996-10-28 |
2014-09-09 |
General Mills, Inc. |
Embedding and encapsulation of sensitive components into a matrix to obtain discrete controlled release particles
|
JPH10158171A
(en)
|
1996-12-02 |
1998-06-16 |
Kita:Kk |
Intraocular administrating agent formulating vitamin d compound therein
|
US6503893B2
(en)
|
1996-12-30 |
2003-01-07 |
Bone Care International, Inc. |
Method of treating hyperproliferative diseases using active vitamin D analogues
|
US20020128240A1
(en)
|
1996-12-30 |
2002-09-12 |
Bone Care International, Inc. |
Treatment of hyperproliferative diseases using active vitamin D analogues
|
US20030129194A1
(en)
|
1997-02-13 |
2003-07-10 |
Bone Care International, Inc. |
Targeted therapeutic delivery of vitamin D compounds
|
US6034075A
(en)
|
1997-03-20 |
2000-03-07 |
The Trustees Of Columbia University In The City Of New York |
Method of treating polycystic ovarian syndrome
|
US5872113A
(en)
|
1997-05-16 |
1999-02-16 |
Syntex (U.S.A.) Inc. |
Fluorinated vitamin D3 analogs
|
PT1009387E
(en)
|
1997-07-02 |
2006-08-31 |
Euro Celtique Sa |
STABILIZED CONTROLLED FREQUENCY FORMULATIONS OF TRAMADOL
|
JPH1175863A
(en)
|
1997-07-10 |
1999-03-23 |
Kyowa Hakko Kogyo Co Ltd |
25-hydroxyvitamin d3-1-alpha-hydroxylase and dna encoding the same
|
US6096876A
(en)
|
1997-08-06 |
2000-08-01 |
Shriners Hospitals For Children |
1-α-hydroxylase materials and methods
|
US20020076442A1
(en)
|
1997-09-02 |
2002-06-20 |
Martin Burke |
Vitamin d3 analog loaded polymer formulations for cancer and neurodegenerative disorders
|
US5919986A
(en)
|
1997-10-17 |
1999-07-06 |
Hoffmann-La Roche Inc. |
D-homo vitamin D3 derivatives
|
JPH11158074A
(en)
|
1997-12-03 |
1999-06-15 |
Hayashi Tomie |
Amino acid-rich active vitamin d potentiation composition
|
US20030059471A1
(en)
|
1997-12-15 |
2003-03-27 |
Compton Bruce Jon |
Oral delivery formulation
|
WO1999049027A1
(en)
|
1998-03-25 |
1999-09-30 |
Cutanogen, Inc. |
Methods for prevention and treatment of cancer
|
EP2340840B1
(en)
|
1998-03-27 |
2012-08-29 |
Oregon Health Sciences University |
Pulse dose Vitamin D drug for the treatment of hyperproliferative skin diseases
|
US6197340B1
(en)
|
1998-05-28 |
2001-03-06 |
Medical Research Institute |
Controlled release lipoic acid
|
US8133694B2
(en)
|
1998-06-25 |
2012-03-13 |
Immundiagnostik Ag |
Functional vitamin D derivatives and method of determining 25-hydroxy- and 1α, 25-dihydroxy vitamin D
|
US6214376B1
(en)
|
1998-08-25 |
2001-04-10 |
Banner Pharmacaps, Inc. |
Non-gelatin substitutes for oral delivery capsules, their composition and process of manufacture
|
EP2153825A1
(en)
|
1998-08-27 |
2010-02-17 |
Pfizer Health AB |
Therapeutic formulation for administering tolterodine with controlled release
|
SE9803871D0
(en)
|
1998-11-11 |
1998-11-11 |
Pharmacia & Upjohn Ab |
Therapeutic method and formulation
|
US6139875A
(en)
|
1998-09-29 |
2000-10-31 |
Eastman Chemical Company |
Aqueous enteric coating composition and low gastric permeability enteric coating
|
AU6283299A
(en)
|
1998-10-01 |
2000-04-17 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
DK1119345T3
(en)
|
1998-10-09 |
2009-08-03 |
Gen Mills Inc |
Encapsulation of delicate liquid constituents in a matrix to obtain separated storage stable particles
|
JP3449253B2
(en)
|
1998-10-29 |
2003-09-22 |
シオノギクオリカプス株式会社 |
Manufacturing method of hard capsule
|
JP2000206312A
(en)
|
1998-11-12 |
2000-07-28 |
Olympus Optical Co Ltd |
Optical element
|
MXPA01006108A
(en)
|
1998-12-17 |
2002-09-18 |
Alza Corp |
Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
|
US6342249B1
(en)
|
1998-12-23 |
2002-01-29 |
Alza Corporation |
Controlled release liquid active agent formulation dosage forms
|
US6432936B1
(en)
|
1999-01-20 |
2002-08-13 |
Wisconsin Alumni Research Foundation |
Crystalline 1α-hydroxyvitamin D2 and method of purification thereof
|
US6248363B1
(en)
|
1999-11-23 |
2001-06-19 |
Lipocine, Inc. |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
PT1180035E
(en)
|
1999-04-01 |
2007-02-28 |
Univ Johns Hopkins |
Non-calcemic, antiproliferative, transcriptionally active sulfur-containing analogs of 1-alpha, 25-dihydroxy vitamin d3
|
US7648826B1
(en)
|
1999-04-02 |
2010-01-19 |
The Regents Of The University Of California |
Detecting CYP24 expression level as a marker for predisposition to cancer
|
DE19916419B4
(en)
|
1999-04-08 |
2005-06-16 |
Schering Ag |
Combination preparation of vitamin D metabolites or vitamin D analogues and an estrogen partial agonist for the treatment of osteoporosis
|
AU5139600A
(en)
|
1999-05-27 |
2000-12-18 |
Drugtech Corporation |
Nutritional formulations
|
US6340473B1
(en)
|
1999-07-07 |
2002-01-22 |
R.P. Scherer Technologies, Inc. |
Film forming compositions comprising modified starches and iota-carrageenan and methods for manufacturing soft capsules using same
|
US6051567A
(en)
|
1999-08-02 |
2000-04-18 |
Abbott Laboratories |
Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
|
US6274169B1
(en)
|
1999-08-02 |
2001-08-14 |
Abbott Laboratories |
Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
|
AU6866900A
(en)
|
1999-08-31 |
2001-03-26 |
Chugai Seiyaku Kabushiki Kaisha |
Soft capsules
|
US20060034937A1
(en)
|
1999-11-23 |
2006-02-16 |
Mahesh Patel |
Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
|
GB0007419D0
(en)
|
2000-03-27 |
2000-05-17 |
Smithkline Beecham Gmbh |
Composition
|
US6375981B1
(en)
|
2000-06-01 |
2002-04-23 |
A. E. Staley Manufacturing Co. |
Modified starch as a replacement for gelatin in soft gel films and capsules
|
EP1301479A2
(en)
|
2000-07-18 |
2003-04-16 |
Bone Care International, Inc. |
STABILIZED 1$g(a)-HYDROXY VITAMIN D
|
US6491950B1
(en)
|
2000-08-07 |
2002-12-10 |
Kos Pharmaceuticals, Inc. |
Controlled release pharmaceutical composition
|
JP4596732B2
(en)
|
2000-08-29 |
2010-12-15 |
日新化成株式会社 |
Hard capsule
|
US6887493B2
(en)
|
2000-10-25 |
2005-05-03 |
Adi Shefer |
Multi component controlled release system for oral care, food products, nutraceutical, and beverages
|
JP2004512354A
(en)
|
2000-10-30 |
2004-04-22 |
ユーロ−セルティーク,エス.エイ. |
Hydrocodone controlled release formulation
|
US6479649B1
(en)
|
2000-12-13 |
2002-11-12 |
Fmc Corporation |
Production of carrageenan and carrageenan products
|
JP2002302447A
(en)
|
2001-04-03 |
2002-10-18 |
Shimizu Pharmaceutical Co Ltd |
Cancer therapeutic agent for topical administration
|
BR0209644A
(en)
|
2001-05-15 |
2004-07-06 |
Warner Lambert Co |
Compaction process for the manufacture of a sodium phenytoin dosage form
|
CA2452577C
(en)
|
2001-07-05 |
2011-04-19 |
Wakunaga Pharmaceutical Co., Ltd. |
Soft capsules
|
CA2454200A1
(en)
|
2001-07-17 |
2003-01-30 |
Teva Pharmaceutical Industries Ltd. |
Dosage forms for immediate gastric release of a calcium transport stimulator coupled with delayed gastric release of a bis-phosphonate
|
US6870833B2
(en)
|
2001-07-20 |
2005-03-22 |
Net2Phone, Inc. |
Active voice messaging
|
US7166585B2
(en)
|
2001-08-22 |
2007-01-23 |
Cytochroma Inc. |
24-Sulfur-substituted analogs of 1α,25-dihydroxy vitamin D3
|
US7033996B2
(en)
|
2001-08-31 |
2006-04-25 |
University Of Medicine & Dentistry Of New Jersey |
Method for the treatment of vitamin D related disease
|
DE10149674A1
(en)
|
2001-10-09 |
2003-04-24 |
Apogepha Arzneimittel Gmbh |
Orally administered composition for sustained release of propiverine, useful for treatment of hypertonic bladder disorders, especially by once-daily administration
|
ATE360000T1
(en)
|
2001-10-12 |
2007-05-15 |
Univ Johns Hopkins |
OXIME ANALOGUE OF 1-ALPHA,25-DIHYDROXY-VITAMIN-D3 WITH LOW CALCEMIC EFFECT
|
US6524788B1
(en)
|
2001-11-02 |
2003-02-25 |
Thomas L. Cantor |
Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
|
US7056655B2
(en)
|
2001-11-02 |
2006-06-06 |
Scantibodies Laboratory, Inc. |
Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
|
ITMI20012366A1
(en)
|
2001-11-09 |
2003-05-09 |
Farmatron Ltd |
THERAPEUTIC SYSTEMS STABILIZED WITH IMMEDIATE RELEASE AND / OR MODIFIED FOR THE ORAL ADMINISTRATION OF ACTIVE AND / OR EXCIPIENT PRINCIPLES AND / OR WINGS
|
KR20100047349A
(en)
|
2001-11-22 |
2010-05-07 |
모리시타 진탄 가부시키가이샤 |
Non-gelatinous capsule film compositions and capsules using the same
|
GB0128415D0
(en)
|
2001-11-27 |
2002-01-16 |
Univ Sheffield |
Medicaments
|
CA2469119A1
(en)
|
2001-12-03 |
2003-06-12 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin d compounds
|
US6627622B2
(en)
|
2002-02-18 |
2003-09-30 |
Wisconsin Alumni Research Foundation |
(20S)-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol and its uses
|
FR2829142B1
(en)
|
2001-12-27 |
2004-02-13 |
Ulice |
FILMOGENEOUS COMPOSITION OF HETEROXYLANE FOR THE MANUFACTURE OF CAPSULES THUS OBTAINED
|
US7632518B2
(en)
|
2002-01-15 |
2009-12-15 |
Dsm Ip Assets B.V. |
25-hydroxy vitamin D3 compositions
|
US6949256B2
(en)
|
2002-01-18 |
2005-09-27 |
Banner Pharmacaps, Inc. |
Non-gelatin capsule shell formulation
|
NO20021592D0
(en)
|
2002-04-04 |
2002-04-04 |
Fmc Biopolymer As |
Polysaccharide Capsules and Method of Preparation thereof
|
AU2003226148A1
(en)
*
|
2002-04-05 |
2003-10-27 |
Merck & Co., Inc. |
Method for inhibiting bone resorption with an alendronate and vitamin d formulation
|
CA2481486C
(en)
|
2002-04-10 |
2012-06-12 |
Fred H. Miller |
Multi-phase, multi-compartment capsular system
|
WO2003093459A1
(en)
|
2002-05-02 |
2003-11-13 |
Cytochroma Inc. |
Stable cytochrome p450 24 (cyp24) expressing cell line and methods and uses thereof
|
AU2003233735A1
(en)
|
2002-06-13 |
2003-12-31 |
Cytochroma Inc. |
24-sulfoximine vitamin d3 compounds
|
BR0312347A
(en)
|
2002-07-05 |
2005-04-12 |
Temrel Inc |
Oral Pharmaceutical Composition, Uses of Coating Thickness of a Dissolving Ph Dependent Coating Material, Coating Material, and Polymethacrylate Material
|
TWI336260B
(en)
*
|
2002-07-25 |
2011-01-21 |
Glaxo Group Ltd |
Dosage form suitable for retaining drug substance
|
MXPA05001191A
(en)
|
2002-07-29 |
2005-09-12 |
Johnson & Johnson |
Methods and dosage forms for controlled delivery of paliperidone.
|
US8268352B2
(en)
|
2002-08-05 |
2012-09-18 |
Torrent Pharmaceuticals Limited |
Modified release composition for highly soluble drugs
|
WO2004028515A1
(en)
|
2002-09-26 |
2004-04-08 |
Young-Kweon Choi |
Matrix type patch for transdermal administration of vitamin d analog and the use thereof
|
US20050101576A1
(en)
|
2003-11-06 |
2005-05-12 |
Novacea, Inc. |
Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes
|
US8999372B2
(en)
|
2002-11-14 |
2015-04-07 |
Cure Pharmaceutical Corporation |
Methods for modulating dissolution, bioavailability, bioequivalence and drug delivery profile of thin film drug delivery systems, controlled-release thin film dosage formats, and methods for their manufacture and use
|
JP2004175750A
(en)
|
2002-11-28 |
2004-06-24 |
Kose Corp |
Dermopathy inhibitor and dermopathy improving agent, and skin care preparation for external use containing them
|
US20050026877A1
(en)
|
2002-12-03 |
2005-02-03 |
Novacea, Inc. |
Pharmaceutical compositions comprising active vitamin D compounds
|
DE10393906T5
(en)
|
2002-12-16 |
2006-01-12 |
Teva Pharmaceutical Industries Ltd. |
A method of increasing the bioavailability of alendronate or another bisphosphonate by administering a pre-dose of a vitamin D derivative
|
DE20321698U1
(en)
*
|
2002-12-16 |
2008-12-24 |
Teva Pharmaceutical Industries Ltd. |
A medicament for increasing the bioavailability of alendronate or another bisphosphonate by administering a pre-dose of a vitamin D derivative
|
WO2004054968A2
(en)
|
2002-12-18 |
2004-07-01 |
Johns Hopkins University |
25-so2-substituted analogs of 1alpha, 25-dihydroxyvitamin d3 (calcitriol)
|
ATE401866T1
(en)
|
2003-02-11 |
2008-08-15 |
Alza Corp |
METHOD AND DOSAGE FORMS WITH MODIFIED LAYER GEOMETRY
|
US7816341B2
(en)
|
2003-04-14 |
2010-10-19 |
Fmc Corporation |
Homogeneous, thermoreversible gel containing reduced viscosity carrageenan and products made therefrom
|
EP1622588A2
(en)
|
2003-04-14 |
2006-02-08 |
Fmc Corporation |
Delivery systems of homogeneous thermoreversible alginate films
|
WO2004098507A2
(en)
*
|
2003-04-30 |
2004-11-18 |
Bioxell S.P.A. |
1,3 aclyated 24-keto-vitamin d3 compounds and methods of use thereof
|
PL1622629T3
(en)
|
2003-05-07 |
2013-12-31 |
Osteologix As |
Controlled-release composition containing a strontium salt
|
EP1479677A1
(en)
|
2003-05-19 |
2004-11-24 |
Aventis Pharma Deutschland GmbH |
New indole derivatives as factor xa inhibitors
|
EP1638508B1
(en)
|
2003-06-16 |
2014-08-13 |
Solx, Inc. |
Shunt for the treatment of glaucoma
|
DK1635787T3
(en)
|
2003-06-26 |
2012-03-26 |
Control Delivery Sys Inc |
Bioerodible delayed release drug delivery systems
|
AU2003903382A0
(en)
|
2003-07-03 |
2003-07-17 |
Medvet Science Pty Ltd |
Inhibition of calcitriol mediated cyp24 induction screening for compounds therefor and uses thereof
|
CA2531136A1
(en)
|
2003-07-04 |
2005-01-13 |
Nycomed Danmark Aps |
Parathyroid hormone (pth) containing pharmaceutical compositions for oral use
|
US20050124591A1
(en)
|
2003-07-29 |
2005-06-09 |
Jin Tian |
Use of vitamin Ds to treat kidney disease
|
US20050148557A1
(en)
|
2003-07-29 |
2005-07-07 |
Jin Tian |
Use of Vitamin Ds to treat kidney disease
|
DK1663182T4
(en)
*
|
2003-09-12 |
2020-02-17 |
Amgen Inc |
Fast dissolving formulation of cinacalcet HCl
|
EP1694333A2
(en)
|
2003-11-25 |
2006-08-30 |
Deltanoid Pharmaceuticals, Inc. |
Methods for reducing body fat using vitamin d compounds
|
CA2494572A1
(en)
|
2003-12-19 |
2005-06-19 |
Cytochroma Inc. |
Cytochrome p450 24 (cyp24) monoclonal antibody and methods and uses thereof
|
US20060009425A1
(en)
|
2004-05-28 |
2006-01-12 |
Leticia Delgado-Herrera |
Oral formulations of paricalcitol
|
WO2005123120A1
(en)
|
2004-06-16 |
2005-12-29 |
Smart Drug Systems Inc. |
Sustained release vaccine composition
|
US20050287213A1
(en)
|
2004-06-28 |
2005-12-29 |
Wong Patrick S |
Dosage forms for low solubility and or low dissolution rate free acid pharmaceutical agents
|
US20060019933A1
(en)
|
2004-07-22 |
2006-01-26 |
David Boardman |
Process for preparing stabilized vitamin D
|
MX2007001138A
(en)
|
2004-07-29 |
2007-04-19 |
Sanofi Aventis |
Pharmaceutical multilayer tablet for controlled release of active ingredients with highly ph-dependent solubility.
|
US8231896B2
(en)
|
2004-11-08 |
2012-07-31 |
R.P. Scherer Technologies, Llc |
Non-gelatin soft capsule system
|
AU2004325362B2
(en)
|
2004-12-03 |
2012-09-06 |
Council Of Scientific And Industrial Research |
Process of preparation of biodegradable films from semi refined kappa carrageenan
|
US8318210B2
(en)
|
2005-02-28 |
2012-11-27 |
Neos Therapeutics, Lp |
Compositions and methods of making sustained release liquid formulations
|
US7745226B2
(en)
|
2005-04-06 |
2010-06-29 |
Quest Diagnostics Investments Incorporated |
Methods for detecting vitamin D metabolites
|
AU2006236564B2
(en)
|
2005-04-15 |
2011-02-17 |
Tolmar, Inc. |
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
|
US20060257481A1
(en)
|
2005-04-21 |
2006-11-16 |
Decode Genetics Ehf. |
Sustained release formulation and dosing schedule of leukotriene synthesis inhibitor for human therapy
|
US9205047B2
(en)
|
2005-04-25 |
2015-12-08 |
The Governing Council Of The University Of Toronto |
Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix
|
US20080134937A1
(en)
|
2005-05-25 |
2008-06-12 |
Joo Hwan Yang |
Cellulose hard capsule enhancing mechanical film strength
|
AR055099A1
(en)
|
2005-07-28 |
2007-08-08 |
Alza Corp |
LIQUID FORMULATIONS FOR THE CONTROLLED ADMINISTRATION OF BENCISOXAZOL DERIVATIVES
|
EP1931711B1
(en)
|
2005-09-29 |
2009-04-08 |
Roche Diagnostics GmbH |
Antibodies against 25-hydroxyvitamin d
|
ITFI20050206A1
(en)
|
2005-09-30 |
2007-04-01 |
Valpharma Sa |
PHARMACEUTICAL COMPOSITION OF CONTROLLED RELEASE OF VENLAFAXINE CHLORIDRATE, AND PROCESS FOR ITS PREPARATION
|
EP1945185B1
(en)
|
2005-10-12 |
2016-02-03 |
Proventiv Therapeutics, LLC |
Methods and articles for treating 25-hydroxyvitamin d insufficiency and deficiency
|
CA2627292C
(en)
|
2005-10-26 |
2012-04-17 |
Banner Pharmacaps, Inc. |
Hydrophilic vehicle-based dual controlled release matrix system
|
CN101351196B
(en)
|
2005-10-26 |
2013-07-03 |
班纳制药公司 |
Lipophilic vehicle-based dual controlled release matrix system serving as capsule fillers
|
KR20080106160A
(en)
|
2005-11-01 |
2008-12-04 |
씨피 켈코 유에스, 인코포레이티드 |
Films and capsules made from modified carboxymethylcellulose materials and methods of making same
|
WO2007068287A1
(en)
|
2005-12-15 |
2007-06-21 |
Laboratoria Qualiphar |
Sustained release vitamin preparation
|
MXPA05014091A
(en)
|
2005-12-20 |
2007-06-20 |
Leopoldo De Jesus Espinosa Abdala |
Pharmaceutical compositions containing synthetic steroid derivatives such as tibolone, minerals such as calcium and the active metabolite of vitamin d (calcitrol) for the prevention and treatment of osteoporosis and menopause.
|
CN101448955A
(en)
|
2006-01-31 |
2009-06-03 |
健康研究股份有限公司 |
Method for identifying altered vitamin D metabolism
|
US7528122B2
(en)
|
2006-02-02 |
2009-05-05 |
Wisconsin Alumni Research Foundation |
Vitamin D analog—NEL, methods and uses thereof
|
DK3095447T3
(en)
|
2006-02-03 |
2022-01-31 |
Opko Renal Llc |
TREATMENT OF VITAMIN D INSUFFICIENTS AND DEFICIENCY WITH 25-HYDROXYVITAMIN D2 AND 25-HYDROXYVITAMIN D3
|
GB0606426D0
(en)
|
2006-03-30 |
2006-05-10 |
Novartis Ag |
Benzimidazole derivatives
|
EP2024436A1
(en)
|
2006-06-06 |
2009-02-18 |
Fmc Corporation |
Kappa-2 carrageenan composition and products made therefrom
|
US20080109983A1
(en)
|
2006-11-10 |
2008-05-15 |
Kegel, Llc |
Zero Turning Radius Lane Maintenance Machine
|
PL2679228T3
(en)
|
2006-06-21 |
2018-07-31 |
Opko Ireland Global Holdings, Ltd. |
Therapy using vitamin D repletion agent and vitamin D hormone replacement agent
|
EP1912400A1
(en)
|
2006-10-10 |
2008-04-16 |
Matsushita Electric Industrial Co., Ltd. |
Method and apparatus for mobile IP route optimization
|
CA2667167C
(en)
|
2006-10-27 |
2014-02-18 |
Pfizer Products Inc. |
Hydroxypropyl methyl cellulose hard capsules and process of manufacture
|
WO2008097646A1
(en)
|
2007-02-09 |
2008-08-14 |
Schering Corporation |
Methods to treat and/or prevent mucositis
|
US8491937B2
(en)
|
2007-02-15 |
2013-07-23 |
Wyeth Llc |
Stability in vitamin and mineral supplements
|
WO2008116113A1
(en)
|
2007-03-20 |
2008-09-25 |
Electrolock, Inc. |
Roebel winding with conductive felt
|
US20100144679A1
(en)
*
|
2007-03-21 |
2010-06-10 |
Duke University |
Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
|
JP5501956B2
(en)
|
2007-04-25 |
2014-05-28 |
シトクロマ インコーポレイテッド |
Controlled release oral composition containing a vitamin D compound and a waxy carrier
|
EP3335712A1
(en)
|
2007-04-25 |
2018-06-20 |
Opko Renal, LLC |
Method of safely and effectively treating and preventing secondary hyperparathyroidism in chronic kidney disease
|
US8592401B2
(en)
|
2007-04-25 |
2013-11-26 |
Proventiv Therapeutics, Llc |
Methods and compounds for vitamin D therapy
|
CN101668532B
(en)
|
2007-04-25 |
2014-08-20 |
赛特克罗公司 |
Composition for treating vitamin d insufficiency and deficiency, secondary hyperparathyroidism and vitamin D responsing diseases and corresponding pharmaceutical purposes
|
US20090004284A1
(en)
|
2007-06-26 |
2009-01-01 |
Watson Pharmaceuticals, Inc. |
Controlled release tamsulosin hydrochloride formulation
|
KR100836960B1
(en)
|
2007-09-07 |
2008-06-10 |
주식회사 서울제약 |
A novel controlled release-niacin formulation
|
EP2042165A1
(en)
|
2007-09-28 |
2009-04-01 |
Swiss Caps Rechte und Lizenzen AG |
Hot-melt filled soft capsules
|
US20090104206A1
(en)
|
2007-10-19 |
2009-04-23 |
Mark Zamoyski |
Bone microenvironment modulated migraine treatments
|
AU2007362356A1
(en)
|
2007-12-12 |
2009-06-18 |
Northern Innovations And Formulations Corp. |
Particles in a capsule
|
EP2240181A1
(en)
|
2008-02-13 |
2010-10-20 |
DSM IP Assets B.V. |
Combined use of 25-hydroxy-vitamin d3 and vitamin d3 for improving bone mineral density and for treating osteoporosis
|
CN107028959A
(en)
|
2008-02-13 |
2017-08-11 |
帝斯曼知识产权资产管理有限公司 |
Hyperglycemia is treated with 25 hydroxycholecalciferols
|
EP2240183A1
(en)
|
2008-02-13 |
2010-10-20 |
DSM IP Assets B.V. |
Combination of vitamin d and 25-hydroxyvitamin d 3
|
EP2249842B1
(en)
|
2008-02-13 |
2016-07-27 |
DSM IP Assets B.V. |
Use of 25-hydroxy-vitamin d3 and vitamin d to affect human muscle physiology
|
US20110118218A1
(en)
|
2008-02-13 |
2011-05-19 |
Neil Robert Buck |
Treating hypertension with 25-hydroxyvitamin d3
|
CN102046812A
(en)
|
2008-04-02 |
2011-05-04 |
赛特克罗公司 |
Methods, compositions, uses, and kits useful for vitamin d deficiency and related disorders
|
US20090258052A1
(en)
|
2008-04-15 |
2009-10-15 |
Osteogenex Inc. |
Compounds and methods for altering bone growth
|
SI2321273T1
(en)
|
2008-07-24 |
2015-03-31 |
Wisconsin Alumni Research Foundation |
Once-a-week administration of 25-hydroxy vitamin d3 to sustain elevated steady-state pharmacokinetic blood concentration
|
WO2010034342A1
(en)
|
2008-09-24 |
2010-04-01 |
Evonik Röhm Gmbh |
Ph-dependent controlled release pharmaceutical opioid composition with resistance against the influence of ethanol
|
EP2179727B1
(en)
|
2008-10-27 |
2013-05-29 |
Roquette Freres |
Water insoluble polymer: modified starch derivative-based film coatings for colon targeting
|
CN102271664B
(en)
|
2009-01-23 |
2013-11-20 |
方济各安吉利克化学联合股份有限公司 |
Controlled release pharmaceutical or food formulation and process for preparation thereof
|
CH700543A2
(en)
|
2009-03-03 |
2010-09-15 |
Innogel Ag |
Film based on starch.
|
TR201904204T4
(en)
|
2009-09-10 |
2019-04-22 |
Dupont Nutrition Usa Inc |
Jointless alginate capsules.
|
IT1396937B1
(en)
|
2009-11-26 |
2012-12-20 |
Bruzzese |
FORMULATIONS OF BISPHOSPHONATES AND VITAMIN D SUITABLE FOR INTERMITTENT ADMINISTRATION BY INTRAMUSCULAR AND SUBCUTANEOUS
|
FR2953139B1
(en)
|
2009-11-27 |
2012-04-13 |
Servier Lab |
PHARMACEUTICAL COMPOSITION COMPRISING STRONTIUM SALT, VITAMIN D AND CYCLODEXTRIN
|
US8101204B2
(en)
|
2010-01-14 |
2012-01-24 |
Karl Wei Cao |
Hard capsule composition and method of use
|
US8101203B2
(en)
|
2010-01-14 |
2012-01-24 |
Karl Wei Cao |
Hard capsule composition and method of use
|
WO2011095388A1
(en)
|
2010-02-04 |
2011-08-11 |
Synthon Bv |
Tolterodine bead
|
LT2552484T
(en)
|
2010-03-29 |
2020-04-27 |
Opko Ireland Global Holdings, Ltd. |
Methods and compositions for reducing parathyroid levels
|
WO2012006475A1
(en)
|
2010-07-07 |
2012-01-12 |
Ardelyx, Inc. |
Compounds and methods for inhibiting phosphate transport
|
KR20120005228A
(en)
*
|
2010-07-08 |
2012-01-16 |
주식회사 네비팜 |
An enteric pharmaceutical composition for the treatment of osteoporosis comprising bisphosphonate and the process thereof
|
CA2807314C
(en)
|
2010-08-04 |
2017-06-20 |
R.P. Scherer Technologies, Llc |
Film-forming composition for soft capsules
|
US20130263297A1
(en)
|
2010-11-10 |
2013-10-03 |
Cedars-Sinai Medical Center |
Methods of treating cancer
|
US20120135103A1
(en)
|
2010-11-30 |
2012-05-31 |
Mead Johnson Nutrition Company |
Staged Infant Feeding Regimen To Promote Healthy Development And Growth
|
CN106924268A
(en)
|
2010-12-06 |
2017-07-07 |
帝斯曼知识产权资产管理有限公司 |
Treated with 25 hydroxycholecalciferols and increase relevant illness with ECF
|
ES2614817T3
(en)
|
2010-12-28 |
2017-06-02 |
Future Diagnostics B.V. |
Vitamin D release reagent
|
WO2012117236A1
(en)
|
2011-03-02 |
2012-09-07 |
D3 Pharma Limited |
Vitamin d composition
|
US8992971B2
(en)
|
2011-04-20 |
2015-03-31 |
Suheung Capsule Co., Ltd. |
Non-animal soft capsule shell composition having improved disintegration and shell hardness
|
CN103781487A
(en)
|
2011-04-20 |
2014-05-07 |
米科生物公司 |
Composition and method for enhancing an immune response
|
CN102771688A
(en)
|
2011-05-13 |
2012-11-14 |
富曼实(上海)商贸有限公司 |
Edible liquid-filled polysaccharide capsule
|
US20130085121A1
(en)
*
|
2011-09-30 |
2013-04-04 |
Jianguo Wang |
Pharmaceutical compositions comprising phosphate binder, calcium receptor-active compound and/or active vitamin d
|
RU2666995C2
(en)
*
|
2012-06-29 |
2018-09-13 |
Висконсин Алюмни Рисерч Фаундейшн |
USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM
|
WO2014029953A1
(en)
|
2012-08-21 |
2014-02-27 |
Cipla Limited |
Hot melt extruded (hme) pharmaceutical composition of cinacalcet
|
KR101847947B1
(en)
|
2013-03-15 |
2018-05-28 |
옵코 아이피 홀딩스 Ⅱ 인코포레이티드 |
Stabilized modified release vitamin d formulation
|
PT106978A
(en)
|
2013-05-31 |
2014-12-02 |
Tecnimede Sociedade Tecnico Medicinal S A |
SOLID ORAL COMPOSITION CONTAINING IBANDRONIC ACID AND VITAMIN D
|
EP2815745A1
(en)
|
2013-06-21 |
2014-12-24 |
Swiss Caps Rechte und Lizenzen AG |
Soft shell capsule and process for its manufacture
|
CN103495176B
(en)
|
2013-10-26 |
2015-01-28 |
中山市凯博思淀粉材料科技有限公司 |
Method for preparing starch-base soft capsules based on co-blending extrusion method
|
CN103520133B
(en)
|
2013-10-26 |
2015-02-04 |
中山市凯博思淀粉材料科技有限公司 |
Preparation method of starch-based soft capsules
|
JP2017523220A
(en)
|
2014-08-07 |
2017-08-17 |
オプコ アイルランド グローバル ホールディングス リミテッド |
Adjunctive therapy with 25-hydroxyvitamin D
|